Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 37,600 shares at $251.15 ($9.6M) on 2021-08-17, disclosed to the SEC on 2021-08-19.
Open-market sale of $9.6M RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $251.15 | 924 | $232K | 2.4% |
| 2 | $251.15 | 924 | $232K | 2.4% |
| 3 | $251.92 | 920 | $232K | 2.4% |
| 4 | $251.92 | 920 | $232K | 2.4% |
| 5 | $253.34 | 4,665 | $1.2M | 12.4% |
| 6 | $253.34 | 4,665 |
| $1.2M |
| 12.4% |
| 7 | $254.09 | 8,580 | $2.2M | 22.8% |
| 8 | $254.09 | 8,580 | $2.2M | 22.8% |
| 9 | $255.07 | 2,231 | $569K | 6.0% |
| 10 | $255.07 | 2,231 | $569K | 6.0% |
| 11 | $256.43 | 194 | $50K | 0.5% |
| 12 | $257.66 | 302 | $78K | 0.8% |
| 13 | $257.66 | 302 | $78K | 0.8% |
| 14 | $258.91 | 634 | $164K | 1.7% |
| 15 | $258.91 | 634 | $164K | 1.7% |
| 16 | $259.93 | 388 | $101K | 1.1% |
| 17 | $259.93 | 388 | $101K | 1.1% |
| 18 | $260.91 | 78 | $20K | 0.2% |
| 19 | $262.31 | 40 | $10K | 0.1% |
| Total | $254.14 avg | 37,600 | $9.6M | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |